The future of research into growth hormone responsiveness.
Decades of experience with growth hormone (GH) therapy have indicated considerable variability in responsiveness to therapy, even within single diagnostic categories, such as GH deficiency, Turner syndrome, intrauterine growth retardation and idiopathic short stature. It is likely that the major explanation for such variability lies in the genetic composition of the patient, including mutations of genes participating in the GH-insulin growth factor I cascade and genetic polymorphisms. Future studies of pharmacogenomic and pharmacoproteomic markers may allow us to better predict and categorize responsiveness to therapy.
Rosenfeld
Ron G
RG
Lucile Packard Foundation for Children's Health, Stanford University, Palo Alto, CA 94301, USA. ron.rosenfeld@lpfch.org
D000818:Animals; D035843:Biomedical Research / Q000639:trends*; D005317:Fetal Growth Retardation / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D011110:Polymorphism, Genetic; D014424:Turner Syndrome / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism
D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I